The race is on to shorten the turnaround time for diagnosis of multidrug-resistant tuberculosis

Journal of Clinical Microbiology

Volumn 53, Issue 12, 2015, Pages 3715-3718

  Somoskovi, Akos ^a   Salfinger, Max ^b  

^a SKARABORG HOSPITAL   (Sweden)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; PYRAZINAMIDE; VIOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; DRUG EFFECT; GENE MUTATION; HUMAN; INHA GENE; KATG GENE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RPOB GENE; SCREENING TEST; LAB ON A CHIP; MOLECULAR DIAGNOSIS; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

HUMANS; LAB-ON-A-CHIP DEVICES; MOLECULAR DIAGNOSTIC TECHNIQUES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84947741931     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02398-15     Document Type: Review

References (28)

1. World Health Organization. (2014). Global tuberculosis report. WHO/HTM/TB/2014.08. World Health Organization, Geneva, Switzerland
2. Scott C, Kirking HL, Jeffries C, Price SF, Pratt R. (2015). Tuberculosis trends-United States, 2014. MMWR Morb Mortal Wkly Rep 64: 265-269
3. Somoskovi A, Parsons LM, Salfinger M. (2001). The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2: 164-168. http://dx.doi.org/10.1186/rr54
4. Böttger EC. (2011). The ins and outs of mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17: 1128-1134. http://dx.doi.org/10.1111/j.1469-0691.2011.03551.x
5. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. (2014). Successful 9-month Bangladesh regimen for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18: 1180-1187. http://dx.doi.org/10.5588/ijtld.14.0100
6. Gumbo T. (2010). New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 54: 1484-1491. http://dx.doi.org/10.1128/AAC.01474-09
7. Müller B, Chihota VN, Pillay M, Klopper M, Streicher EM, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, Gagneux S, van Helden PD, Warren RM. (2013). Programmatically selected multidrug-resistant strains drive the emergence of extensively drugresistant tuberculosis in South Africa. PLoS One 8: e70919. http://dx.doi.org/10.1371/journal.pone.0070919
8. Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. (2014). Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol 52: 1846-1852. http://dx.doi.org/10.1128/JCM.03005-13
9. Vadwai V, Boehme C, Nabeta P, Shetty A, Rodrigues C. (2012). Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases. Indian J Med Res 135: 560-561
10. Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, Van Deun A, Barrera L, Boulahbal F, Richter E, Martín-Casabona N, Arias F, Zemanova I, Drobniewski F, Santos Silva A, Coulter C, Lumb R, Cegielski JP. (2012). Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis 16: 355-357. http://dx.doi.org/10.5588/ijtld.11.0542
11. Mukinda FK, Theron D, van Der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS. (2012). Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 16: 196-202. http://dx.doi.org/10.5588/ijtld.11.0116
12. Bártfai Z, Somoskövi A, Ködmön C, Szabó N, Puskás E, Kosztolányi L, Faragó E, Mester J, Parsons LM, Salfinger M. (2001). Molecular characterization of rifampin-resistant isolates of mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol 39: 3736-3739. http://dx.doi.org/10.1128/JCM.39.10.3736-3739.2001
13. Van Deun A, Aung KJ, Hossain A, De Rijk P, Gumusboga M, Rigouts L, De Jong BC. (2015). Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 19: 185-190. http://dx.doi.org/10.5588/ijtld.14.0651
14. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. (2006). Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 44: 4459-4463. http://dx.doi.org/10.1128/JCM.01506-06
15. Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, Bonnet M, Niemann S. (2015). Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med 372: 1181-1182. http://dx.doi.org/10.1056/NEJMc1413930
16. Heysell SK, Ahmed S, Ferdous SS, Khan MS, Rahman SM, Gratz J, Rahman MT, Mahmud AM, Houpt ER, Banu S. (2015). Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS One 10: e0116795. http://dx.doi.org/10.1371/journal.pone.0116795
17. Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. (2012). Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 5186-5193. http://dx.doi.org/10.1128/AAC.05385-11
18. Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y. (2012). Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother 56: 5465-5475. http://dx.doi.org/10.1128/AAC.01300-12
19. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. (2013). Contribution of moxifloxacin or levofloxacin in secondline regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 188: 97-102. http://dx.doi.org/10.1164/rccm.201212-2328OC
20. Mitarai S, Kato S, Ogata H, Aono A, Chikamatsu K, Mizuno K, Toyota E, Sejimo A, Suzuki K, Yoshida S, Saito T, Moriya A, Fujita A, Sato S, Matsumoto T, Ano H, Suetake T, Kondo Y, Kirikae T, Mori T. (2012). Comprehensive multicenter evaluation of a new line probe assay kit for identification of mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 50: 884-890. http://dx.doi.org/10.1128/JCM.05638-11
21. Zhou M, Geng X, Chen J, Wang X, Wang D, Deng J, Zhang Z, Wang W, Zhang XE, Wei H. (2011). Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One 6: e27654. http://dx.doi.org/10.1371/journal.pone.0027654
22. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, DAmbrosio L, Lange CG, Bauer M, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. (2013). Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrugresistant TB outcomes. Eur Respir J 42: 156-168. http://dx.doi.org/10.1183/09031936.00134712
23. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. (2012). gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of mycobacterium tuberculosis. J Antimicrob Chemother 67: 1088-1093. http://dx.doi.org/10.1093/jac/dks033
24. Yew WW, Nuermberger E. (2013). High-dose fluoroquinolones in shortcourse regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 17: 853-854. http://dx.doi.org/10.5588/ijtld.13.0301
25. Maus CE, Plikaytis BB, Shinnick TM. (2005). Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 3192-3197. http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005
26. Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. (2012). Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 18: 193-197. http://dx.doi.org/10.1089/mdr.2011.0063
27. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. (2014). Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 59: 9-15. http://dx.doi.org/10.1093/cid/ciu209
28. Cabibbe AM, Miotto P, Moure R, Alcaide F, Feuerriegel S, Pozzi G, Nikolayevskyy V, Drobniewski F, Nieman S, Reither K, Cirillo DM, TB-REST Consortium, TB-CHILD Consortium. (2015). Lab-on-chipbased platform for fast molecular diagnosis of multidrug-resistant tuberculosis. J Clin Microbiol 53: 3876-3880. http://dx.doi.org/10.1128/JCM.01824-15